Skip to main content
Premium Trial:

Request an Annual Quote

BioInform's Licensing Roundup: July and August's Software Deals


Takeda San Francisco has licensed Ariadne’s Pathway Studio software.

The biologics discovery arm of Takeda plans to use the software to support its therapeutics discovery for cancer, inflammatory disease, and metabolic disease.

ChemAxon said that the Broad Institute will license its platform, discovery toolkits, and desktop applications for institute-wide use.

Specifically, the Broad will use ChemAxon's technology, including the JChem toolkit, to support its small-molecule registration system and other aspects of its Chemical Biology Platform.

The Catholic Health Initiatives’ Institutes for Research and Innovation’s Center for Translational Research will use BioFortis's Labmatrix software as part of its personalized medicine research effort.

Labmatrix is a web-based software that lets users manage and integrate clinical, specimen, and molecular assay datasets and interface the data with other systems such as electronic medical records, genomic or proteomic databases, and laboratory information management systems.

As part of the agreement, the partners plan to integrate the software with in-network hospitals’ electronic medical records systems.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.